Chemical name: 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile;
Formula: C17H11N5
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid

FEMARA 5mg – PARA PHARMA

Introduction: Femara 5mg, manufactured by Para Pharma, is a potent medication containing Letrozole as its active ingredient. Letrozole is classified as an aromatase inhibitor and is widely used in the treatment of hormone-sensitive breast cancer in postmenopausal women. Femara plays a crucial role in hormonal therapy by suppressing estrogen production, thereby inhibiting the growth of estrogen-dependent tumors.

Active Substance: The primary active substance in Femara 5mg is Letrozole, a non-steroidal aromatase inhibitor. Letrozole works by selectively inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogens. By blocking estrogen synthesis, Letrozole helps reduce estrogen levels in the body, thereby depriving estrogen-dependent tumors of the hormones they need to grow and proliferate.

Form and Packaging: Femara is available in the form of 50 pills, each containing 5 mg of Letrozole. The tablets are typically round and film-coated for ease of swallowing. The packaging is designed to ensure the integrity and stability of the medication, with clear labeling indicating the dosage strength and manufacturer.

Indications: Femara 5mg is primarily indicated for the treatment of:

1. Breast Cancer: Femara is indicated for use in postmenopausal women with hormone receptor-positive early breast cancer or advanced breast cancer. It may be used as adjuvant therapy following surgery or as first-line or subsequent therapy for metastatic breast cancer.

Mechanism of Action: Letrozole exerts its therapeutic effects through inhibition of aromatase, the enzyme responsible for converting androgens into estrogens. By blocking aromatase activity, Letrozole reduces circulating estrogen levels in postmenopausal women, which in turn inhibits the growth of estrogen-sensitive breast cancer cells. This leads to tumor regression and improved outcomes in patients with hormone receptor-positive breast cancer.

Dosage and Administration: The recommended dosage of Femara 5mg for breast cancer treatment is typically 2.5 mg once daily, administered orally with or without food. Treatment duration may vary depending on the stage and severity of the cancer, as well as individual patient factors. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional to ensure optimal treatment outcomes.

Safety Considerations: While Femara is generally well-tolerated, it may cause certain side effects in some individuals. Common side effects may include hot flashes, fatigue, joint pain, nausea, and headache. Rare but more severe side effects such as bone fractures, osteoporosis, and cardiovascular events may occur, particularly with prolonged use.

Patients should be monitored regularly for signs of adverse effects, and appropriate supportive care measures may be implemented as needed. It is essential for patients to discuss any concerns or potential side effects with their healthcare provider.

Conclusion: Femara 5mg, containing Letrozole as the active substance, plays a crucial role in the treatment of hormone-sensitive breast cancer in postmenopausal women. By inhibiting estrogen synthesis, Letrozole helps deprive estrogen-dependent tumors of the hormones they need to grow and proliferate, leading to improved outcomes in patients with hormone receptor-positive breast cancer. As with any medication, it is essential for patients to use Femara under the supervision of a healthcare professional and to adhere to prescribed dosage and administration guidelines to ensure safe and effective treatment outcomes.